Patents by Inventor Benjamin Levine Ebert

Benjamin Levine Ebert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220170100
    Abstract: The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.
    Type: Application
    Filed: August 16, 2021
    Publication date: June 2, 2022
    Inventors: Benjamin Levine Ebert, Siddhartha Jaiswal, Sekar Kathiresan
  • Publication number: 20220017938
    Abstract: In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.
    Type: Application
    Filed: October 7, 2021
    Publication date: January 20, 2022
    Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: TARJEI MIKKELSEN, BENJAMIN LEVINE EBERT, QUINLAN SIEVERS
  • Patent number: 11168345
    Abstract: In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.
    Type: Grant
    Filed: September 9, 2016
    Date of Patent: November 9, 2021
    Assignees: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Tarjei Mikkelsen, Benjamin Levine Ebert, Quinlan Sievers
  • Patent number: 10711308
    Abstract: Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.
    Type: Grant
    Filed: June 15, 2012
    Date of Patent: July 14, 2020
    Assignees: BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Rafael Bejar, Benjamin Levine Ebert, Kristen Stevenson, Donna Neuberg
  • Publication number: 20190274292
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: May 10, 2019
    Publication date: September 12, 2019
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • Patent number: 10334829
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: April 17, 2018
    Date of Patent: July 2, 2019
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Publication number: 20190106710
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to enable genome engineering in an organism to recapitulate the genetic complexity of disease or a condition and further interrogate gene function.
    Type: Application
    Filed: June 7, 2018
    Publication date: April 11, 2019
    Applicants: THE BROAD INSTITUTE, INC., MASSACHUSETTS INSTITUTE OF TECHNOLOGY, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Feng Zhang, Benjamin Levine Ebert, Dirk Heckl
  • Publication number: 20190071731
    Abstract: In one aspect, the invention features a method for identifying a drug-modulated polypeptide substrate of cereblon (CRBN). In another aspect, the invention features a method of identifying a polypeptide target of a modulator of CRBN. In yet another aspect, the invention provides methods of monitoring or characterizing the sensitivity of a subject to a modulator of CRBN.
    Type: Application
    Filed: September 9, 2016
    Publication date: March 7, 2019
    Applicants: THE BROAD INSTITUTE, INC., PRESIDENT AND FELLOWS OF HARVARD COLLEGE, THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: TARJEI MIKKELSEN, BENJAMIN LEVINE EBERT, QUINLAN SIEVERS
  • Publication number: 20180343839
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: April 17, 2018
    Publication date: December 6, 2018
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • Patent number: 9974289
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: May 22, 2018
    Assignees: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc.
    Inventors: Benjamin Levine Ebert, Jan Krönke, Steven A. Carr, Namrata D. Udeshi, Emma Fink
  • Publication number: 20180010185
    Abstract: The invention relates to method for identifying and selecting a subject with increased risk of developing a cardiometabolic disease and optionally, providing a personalized medicine method, which may involve sequencing at least part of a genome of one or more cells in a blood sample of the subject and identifying from said sequencing one or more mutations in one or more somatic mutations.
    Type: Application
    Filed: November 25, 2015
    Publication date: January 11, 2018
    Inventors: Benjamin Levine Ebert, Siddhartha Jaiswal, Sekar Kathiresan
  • Publication number: 20160338326
    Abstract: The present invention features a knock-in mouse comprising a mutation in an endogenous CRBN locus and methods of use thereof.
    Type: Application
    Filed: March 18, 2016
    Publication date: November 24, 2016
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, JAN KRÖNKE, STEVEN A. CARR, NAMRATA D. UDESHI, EMMA FINK
  • Publication number: 20160282354
    Abstract: The present invention features compositions and methods for identifying a subject having a B cell neoplasia or related condition responsive to treatment with lenalidomide and lenalidoinide-related compounds.
    Type: Application
    Filed: November 7, 2014
    Publication date: September 29, 2016
    Applicants: THE BROAD INSTITUTE, INC., THE BRIGHAM & WOMEN'S HOSPITAL, INC.
    Inventors: BENJAMIN LEVINE EBERT, STEVEN A. CARR, JAN KRÖNKE, NAMRATA D. UDESHI, EMMA FINK
  • Publication number: 20160168594
    Abstract: The invention provides for delivery, engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are delivery systems and tissues or organ which are targeted as sites for delivery. Also provided are vectors and vector systems some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells to enable genome engineering in an organism to recapitulate the genetic complexity of disease or a condition and further interrogate gene function.
    Type: Application
    Filed: December 16, 2015
    Publication date: June 16, 2016
    Inventors: Feng Zhang, Benjamin Levine Ebert, Dirk Heckl
  • Publication number: 20140127690
    Abstract: Somatic non-silent mutations on selected biomarkers are reliable indicators for the overall survival of Myelodysplastic Syndrome subjects.
    Type: Application
    Filed: June 15, 2012
    Publication date: May 8, 2014
    Applicants: THE BRIGHAM AND WOMEN'S HOSPITAL, INC., DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: Rafael Bejar, Benjamin Levine Ebert, Kristen Stevenson, Donna Neuberg
  • Publication number: 20120237488
    Abstract: A method for determining prognosis in a subject having a hematological cancer comprising: a) determining an expression profile by measuring the gene expression levels of a set of genes selected from a leukemic stem cell (LSC) gene signature marker set or an hematopoietic stem cell (HSC) gene signature marker set, in a sample from a subject; and b) classifying the subject as having a good prognosis or a poor prognosis based on the expression profile; wherein a good prognosis predicts an increased likelihood of survival within a predetermined period after initial diagnosis and poor prognosis predicts a decreased likelihood of survival within the predetermined period after initial diagnosis.
    Type: Application
    Filed: December 3, 2010
    Publication date: September 20, 2012
    Applicants: UNIVERSITY HEALTH NETWORK, THE BRIGHAM AND WOMEN'S HOSPITAL, INC., THE HOSPITAL FOR SICK CHILDREN
    Inventors: John Dick, Kolja Eppert, Igor Jurisica, Levi David Waldron, Mark Minden, Eric Lechman, Bjorn Nilsson, Benjamin Levine Ebert, Katsuto Takenaka, Jayne S. Danska